P3.02c-043 Immunotherapy in Non-Small Cell Lung Cancer: A New Approach and a New Challenge
نویسندگان
چکیده
منابع مشابه
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
In this editorial, we highlight the exciting advances in immunotherapy for the treatment of non-small cell lung cancer, with nivolumab being the first immunotherapeutic agent to be approved by the US FDA for the treatment of squamous lung cancer and several other promising immune checkpoint inhibitors currently being evaluated in clinical trials. The next step is to understand the mechanisms of...
متن کاملImmunotherapy for Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide, and more than 80% of cases are of non-small cell lung cancer. Although chemotherapy and molecularly targeted therapy may provide some benefit, there is a need for newer therapies for the treatment of patients with advanced NSCLC. Immunotherapy aims to augment the recognition of cancer as foreign, to stimulate immune respons...
متن کاملNew approaches in cancer immunotherapy: review article
Cancer immunotherapy refers to any intervention that leverages the immune system to eliminate a malignancy. Successful cancer immunotherapies generate an anti-cancer response that is systemic, specific, and durable and overcome to the primary limitations of traditional cancer treatment modalities. In this review paper, the effective methods in immune system to treat cancer, such as immunosuppre...
متن کاملtyrosine kinase inhibitors for non-small cell lung cancer and eye metastasis; disease relapse or a new entity?
lung cancer is still diagnosed in advanced stage and most patients do not have the opportunity for surgical treatment. although in the recent years new diagnostic equipment is available such as the radial and linear endobronchial ultrasound (ebus) and electromagnetic fiberoptic bronchoscopy. however; novel targeted therapies with tyrosine kinase inhibitors of second generation and immunotherapy...
متن کاملTargeted therapies and immunotherapy in non-small-cell lung cancer
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumour...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.1838